Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study.
Burisch JGediminas KiudelisLimas KupcinskasHendrika Adriana Linda KievitKarina Winther AndersenVibeke AndersenRiina SalupereNatalia PedersenJens KjeldsenRenata D'IncàDaniela ValpianiDoron SchwartzSelwyn OdesJóngerð OlsenKári Rubek NielsenZsuzsanna VeghPeter Laszlo LakatosAlina TocaSvetlana TurcanKonstantinos H KatsanosDimitrios K ChristodoulouMathurin FumeryCorinne Gower-RousseauStefania Chetcuti ZammitPierre EllulCarl ErikssonJonas HalfvarsonFernando Jose MagroDana DuricovaMartin BortlikAlberto FernandezVicent Hernandez RamirezSally MyersShaji SebastianPia OksanenPekka CollinAdrian GoldisRavi MisraNaila ArebiIoannis P KaimakliotisInna NikuinaElena BelousovaMarko BrinarSilvija Cukovic-CavkaEbbe LangholzPia Munkholmnull nullPublished in: Gut (2018)
Despite patients being treated early and frequently with immunomodulators and biological therapy in Western Europe, 5-year outcomes including surgery and phenotype progression in this cohort were comparable across Western and Eastern Europe. Differences in treatment strategies between Western and Eastern European centres did not affect the disease course. Treatment with immunomodulators reduced the risk of surgery and hospitalisation.
Keyphrases
- south africa
- minimally invasive
- newly diagnosed
- end stage renal disease
- coronary artery bypass
- chronic kidney disease
- ejection fraction
- stem cells
- type diabetes
- prognostic factors
- coronary artery disease
- surgical site infection
- skeletal muscle
- bone marrow
- insulin resistance
- smoking cessation
- combination therapy
- replacement therapy